Guidelines for poster preparation
Please prepare your poster in A1 portrait format (59cm wide x 84cm long). Do not laminate your poster. Further information about poster sizes can be found on the following link:
Posters larger than A1 will only be displayed subject to the availability of space.
Maximum capacity 30 A1 potrait posters
Please ensure you have appropriate permissions for the publication of your abstract from the original copyright holders. Should you wish your abstract not to be published, please notify us in writing at the time of abstract submission.
Poster presenters will be required to send us their poster as PDF at least two weeks before the event. The posters will be made available via the event website or other electronic media after the event (see copyright information).
Posters will be displayed for the full duration of the conference.Titles of accepted poster abstracts will be displayed below.
(Presenters in Bold)
If your abstract has been accepted for presentation but it does not appear in the list below, please let us know as soon as possible by email on CRISPR@LPMHealthcare.com.
Targeted genome editing with engineered endonucleases
Amna A Alotiby, Lucy C Fairclough, Ian Todd, Paddy J Tighe
MBTI Research Group, School of Life Sciences, University of Nottingham, Nottingham
Evidence from more than 700 genome editing experiments using CRISPR/Cas – lessons learned
Daniel H Lackner1, Paloma Guzzardo1, Richard Schobesberger1, Ana Lapao1, Philipp Hainzl1, Lilian Lohninger1, Sebastian MB Nijman2, Thijn R Brummelkamp3, Tilmann Bürckstümmer1
1Horizon Genomics, Campus Vienna Biocenter 5, 1030 Vienna, Austria
2Ludwig Cancer Research, Oxford Branch, Old Road Campus Research Building, Headington OXF, OX3 7DQ, UK
3Netherlands Cancer Institute (NKI), Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
Enhanced engineering success with optimized cell line screening procedure
Thibault Laurent, Aleksander Gontarczyk, Tim Scales, Jane Elliott, Holly M Astley, Chris E Lowe, Kyla Grimshaw
Horizon Discovery Group plc, Cambridge, UK
Using the CRISPR technology to develop cellular models of Hypertrophic Cardiomyopathy
Sandra B Martins, Teresa Carvalho, Rita M Almeida, Catarina Santos and Maria Carmo-Fonseca
Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
CRISPRdirect: web-based tool for designing CRISPR/Cas guide RNA with reduced off-target sites
Yuki Naito1,2, Kimihiro Hino3, Kumiko Ui-Tei3, Hidemasa Bono1,2
1Database Center for Life Science (DBCLS), and
2National Institute of Genetics, Research Organization of Information and Systems, 1111 Yata, Mishima, Shizuoka 411-8540, Japan
3Department of Biological Sciences, Graduate School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
Highly efficient gene inactivation by adenoviral CRISPR/Cas9 in a human primary cell phenotypic assay
Olaf Voets, Frans Tielen1, Edo Elstak, Julian Benschop, Max Grimbergen, Jan Stallen, Richard Janssen, Andre van Marle, Christian Essrich
Galapagos BV, Darwinweg 24, 2333 CR Leiden, The Netherlands